Complete pathological remission after neoadjuvant ensartinib in patients with locally advanced lung adenocarcinoma and with CTLC-ALK and ALK-DHX8 rearrangements

Eur J Cancer. 2022 Jul:169:131-134. doi: 10.1016/j.ejca.2022.04.012. Epub 2022 May 11.

¹ Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.
² Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China; Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China; Early-Stage Lung Cancer Center, The Second Xiangya Hospital of Central South University, Changsha, China.
³ Department of Pathology, The Second Xiangya Hospital of Central South University, Changsha, China.
⁴ Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China; Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China; Early-Stage Lung Cancer Center, The Second Xiangya Hospital of Central South University, Changsha, China. Electronic address: pengmuyun@csu.edu.cn.

No abstract available

Publication types